Turn Therapeutics (TTRX) Consolidated Net Income (2024 - 2026)
Turn Therapeutics' quarterly Consolidated Net Income came in at -$1.2 million in Q1 2026, down 215.0% year-on-year from $1.0 million in Q1 2025, and up 45.1% quarter-over-quarter from -$2.2 million in Q4 2025.
Turn Therapeutics has reported Consolidated Net Income for 3 years, with the latest figure at -$1.2 million in Q1 2026.
- For the quarter ending Q1 2026, Consolidated Net Income fell 215.0% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (changed N/A YoY), and the FY2025 full-year result was -$5.8 million, down 229.62% from the prior year.
- Consolidated Net Income for Q1 2026 stood at -$1.2 million, up from -$2.2 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$323130.0 in Q4 2024, with the low at -$2.2 million in Q4 2025.
- Average Consolidated Net Income over 3 years is -$1.1 million, with a median of -$931453.0 recorded in 2024.
- Peak annual rise in Consolidated Net Income reached 186.36% in 2025, while the deepest fall reached 574.46% in 2025.
- Tracing TTRX's Consolidated Net Income over 3 years: stood at -$323130.0 in 2024, then sank by 574.46% to -$2.2 million in 2025, then jumped by 45.1% to -$1.2 million in 2026.
- The last three Consolidated Net Income figures came in at -$1.2 million (Q1 2026), -$2.2 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Turn Therapeutics | 188.06 Mn | 188.06 Mn | - | -1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.20 Mn |
| Dec 31, 2025 | -2.18 Mn |
| Sep 30, 2025 | -1.91 Mn |
| Mar 31, 2025 | -379,832.00 |
| Dec 31, 2024 | -323,130.00 |
| Sep 30, 2024 | -666,442.00 |